TABLE 4.

Diagnostic value of miR-1246 in cancers (NMRD: non-malignant respiratory diseases, NSCLC: non-small cell lung cancer, ESCC: esophageal squamous cell carcinoma, ETR: Early tumor recurrence, HGSOC: High-grade serous ovarian carcinoma).

Tumor type	Numbers of clinical samples	Distinguish between	Area under curve	Sensitivity (%)	Specificity (%)	Accuracy (%)	References
Colorectal cancer (CRC)	Sera of 37 CRC patients and 30 healthy controls	37 CRC patients vs. healthy controls	—	100	80	—	Salah et al. (2020)
	Serum samples from 43 CRC patients	Chemoresistant CRC patients vs. chemosensitive group	0.749	—	—	—	Jin et al. (2019)
Lung cancer	105 NSCLC patients, 50 NMRD patients, and 50 healthy controls	NSCLC patients vs. healthy controls	0.827	—	—	—	Huang and Qu (2020)
		NSCLC patients vs. NMRD patients	0.757	—	—	—
	52 NSCLC patients and 45 healthy controls	NSCLC patients vs. healthy controls	0.6761	—	—	—	Zheng et al. (2021)
Esophageal cancer	Serum from 55 ESCC patients and 39 healthy controls	ESCC patients vs. healthy controls	0.816	72.7	69.2	—	Hoshino et al. (2020a)
	Serum from 101 ESCC patients and 34 healthy controls	ESCC patients vs. healthy controls	0.779	71.3	70.6	—
	101 ESCC patients and 35 healthy controls	ESCC patients vs healthy controls	0.754	71.29	73.91	—	Hoshino et al. (2020b)
	101 ESCC patients and 46 healthy controls	ESCC patients vs. healthy controls	0.754	71.3	73.9	—	Takeshita et al. (2013)
	serum 72 ESCC patients and 50 healthy controls	ESCC patients vs. healthy controls	0.912	91.7	76.0	—	Hoshino et al. (2021)
	urine from 72 ESCC patients and 50 healthy controls	ESCC patients vs. healthy controls	0.823	90.3	62.0	—
Prostate cancer (PCa)	26 lymph node metastatic PCa, 43 non-metastatic PCa, and 8 healthy controls	Non-metastatic vs. localized metastatic PCa patients	0.648	81	∼59	—	Bhagirath et al. (2018)
	43 metastatic castration-resistant PCa cases	Normal and aggressive PCa patients and normal controls	0.933	88.37	100	—
Breast cancer	32 trastuzumab-resistant patients and 36 trastuzumab sensitive patients	Trastuzumab-resistant patients vs. trastuzumab sensitive patients	0.750	78.1	75	—	Zhang et al. (2020)
	Plasma from 16 breast cancer patients and 16 healthy controls	Breast cancer patients vs. healthy controls	0.69	—	—	—	Hannafon et al. (2016)
	serum from 100 breast cancer patients and 40 healthy controls	Breast cancer patients vs. healthy controls	0.904	93.0	75.0	—	Fu et al. (2016)
	Plasma from 146 breast cancer patients and 90 healthy controls	Breast cancer patients vs. healthy controls	0.95	85.0	93.0	88.0	Jang et al. (2021)
	Plasma from 80 breast cancer patients and 56 healthy controls	Breast cancer patients vs. healthy controls	0.963	86.0	96.0	90.0
	859 BC patients and 1,791 healthy controls	Breast cancer patients vs. healthy controls	0.967	89.8	91.7	—	Cui et al. (2018)
Hepatocellular carcinoma (HCC)	Serum from 33 primary HCC patients, 22 metastatic liver tumor patients	HCC patients vs. metastatic liver tumor patients	0.708	72.2	67.8	—	Ahmed et al. (2019)
	16 HCC patients and 27 cirrhosis patients	HCC patients vs. cirrhotic patients	0.97	86.7	84.6	85.7	Moshiri et al. (2018)
	29 HCC patients and 25 healthy controls	HCC patients vs. healthy controls	0.83	57.1	78.6	71.4
	Serum from 50 HCC patients and 50 healthy controls	HCC patients vs. healthy controls	0.865	82.0	80.0	—	Chen et al. (2021b)
	37 HCC patients with ETR and 84 HCC patients without ETR	HCC patients with ETR vs. HCC patients without ETR	0.762	54.1	77.4	—	Chuma et al. (2019)
	62 HCC patients received liver transplantation	High group vs. low group for tumor recurrence	0.775	88.9	66.0	—	Ng et al. (2016)
Pancreatobiliary tract cancer	12 pancreatobiliary tract cancer patients and 13 healthy controls	Pancreatobiliary tract cancer patients vs. healthy controls	0.814	0.667	1.000	—	Machida et al. (2016)
Ovarian cancer (OC)	Serum from 168 HGSOC patients and 65 Healthy controls	HGSOC patients vs. Healthy controls	0.89	87	77	84	Todeschini et al. (2017)